



(51) International Patent Classification:

C12N 5/0783 (2010.01) C07K 14/47 (2006.01)
A61P 35/00 (2006.01) C07K 14/705 (2006.01)
A61K 35/17 (2015.01) C07K 14/715 (2006.01)
A61P 31/12 (2006.01)

(21) International Application Number:

PCT/EP2020/087151

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19217356.5 18 December 2019 (18.12.2019) EP

(71) Applicant: **CORDES BIOTECH A/S** [DK/DK]; Alexandervej 1, 2920 Charlottenlund (DK).

(72) Inventors: **CORDES, Ulrik**; c/o Cordes Biotech A/S, Alexandervej 1, 2920 Charlottenlund (DK). **FRIESE, Christina**; Masnedogade 28, 1.th., 2100 Copenhagen Ø

(DK). **KIRKETERP-MØLLER, Nikolaj**; Slangerrupgade 16, 2.tv., 2200 Copenhagen N (DK). **HEEKE, Christina**; Frederikssundsvej 84a, 3.2, 2400 Copenhagen NV (DK).

(74) Agent: **AERA A/S**; Niels Hemmingsens Gade 10, 5th floor, 1153 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: IMPROVED PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE




Fig. 1

(57) Abstract: The present invention is targeted towards reinvigorating exhausted Tumor Infiltrating Lymphocytes (TILs) *in vitro* by co-culturing excised TIL containing tumor fragments with checkpoint inhibitors, stimulating the TILs with other interleukins known to revert T cell exhaustion), and/or inhibiting the effect of regulatory T cells secreted factors (such as IL-10) thereby creating a favorable tumor microenvironment (TME) where exhausted T-cells can expand faster and to higher numbers than currently established TIL expansion protocols.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*